

Index of Contributors

(Italicized numbers refer to comments made in discussion)

Aikawa, M. 578-585

Akakura, H. 394-398

Akita, H. 626-629

Albers, J. J. 407-417

Ali Elsayed, Y. 185-192

Ando, J. 148-156, *156*

Arai, H. 294-300

Arai, T. 599-602, 606-608

Arisaka, T. 543-554

Asada, Y. 74-85

Asaoka, H. 226-238

Ashikaga, T. 383-392

Baker, J. E. 474-480, 559-561

Balyasnikova, I. V. 12-37

Barbee, K. A. 86-102

Bini, A. 293, 461-471, *471-473*

Bouché, A. 367-381

Brown, B. G. *312, 332, 355, 407-417, 417-418, 428*

Buchwald, H. *4-5, 331, 342-355, 355-356, 418*

Bystrevskaya, V. B. 12-37

Byzova, T. V. 12-37

Campos, C. T. for the POSCH Group
342-355

Carmeliet, P. 367-381

Chlopicki, S. 194-206

Collen, D. 367-381, *381-382*

Collins, T. 122-131

Currier, J. W. 419-427

Cybulsky, M. I. 122-131

Davies, P. F. *55-56, 86-102, 102-103, 156-157, 183, 382*

De Clercq, C. 367-381

Doi, T. 226-238

Doi, Y. 634-636

Eastman, A. 474-480, 559-561

Egashira, K. 622-625

Ejiri, N. 595-598

Emi, M. 226-238

Endo, Y. 630-633

Epstein, F. H. 482-490

Faxon, D. P. *216, 419-427, 427-428*

Fujinuma, Y. 595-598

Fujisawa, K. 562-570, 595-598

Fujishima, M. 634-636

Fujita, H. 133-147

Fujitani, N. 534-537

Furuya, M. 517-523

Galis, Z. S. 158-168, 501-507

Gimbrone, M. A. *39, 121, 122-131, 131-132, 156-157, 282, 312, 381-382, 471, 480-481, 541-542*

Gotoda, T. 357-364

Griem, M. L. 86-102

Gryglewski, R. J. 194-206, *207, 392-393*

Haga, H. 626-629

Hagiwara, H. 104-120

Haibach, C. 301-311

Hakoi, K. 640-644

Hamazaki, Y. 630-633

Han, S.-Z. 447-460

Harada, K. 357-364

Harada-Shiba, M. 429-439

Haraki, T. 333-341

Haraoka, S. 40-55

Hashimoto, H. 626-629

Hasler-Rapacz, J. 283-292

Hata, A. 383-392

Hata, Y. *183-184*

Hatano, H. 226-238

Haust, D. *168, 300, 331, 471*

Hayashi, T. 74-85

Higashino, H. 534-537

Hillger, L. 407-417

Hirai, A. 571-574

Hirano, K. 599-602, 606-608

Hirata, K. 555-558

Hirose, S. 543-554

Honbou, N. 517-523

Honda, M. 226-238

Honye, J. 494-497

Hoshino, A. 217-224

Hosoda, S. 208-216

Hosoi, T. 530-533

Ichikawa, K. 185-192

Iijima, H. 217-224

Iino, K. 634-636

Ikeda, M. 637-639

Ikewaki, K. 441-446, 626-629

Ilyinskaya, O. P. 12-37

Imanaka, T. 277-281, 524-525

Inaba, T. 357-364

Inazu, A. 333-341

Inoue, S. 530-533, 592-594

Ishibashi, T. 630-633
 Ishigami, M. 606-608
 Ishikawa, T. 626-629
 Itakura, H. 226-238
 Ito, T. 626-629
 Iwasaki, K. 524-525
 Iwase, M. 634-636

Janssen, S. 367-381
 Jimi, S. 609-612
 Jokaji, H. 394-398

Kajinami, K. 333-341
 Kameda-Takemura, K. 599-602, 606-608
 Kamiya, A. 148-156
 Kangawa, K. 517-523
 Kanmatsuse, K. 494-497
 Karaki, H. 447-460
 Kario, K. 398
 Katayama, M. 555-558
 Kato, K. 185-192
 Katsura, Y. 57-72
 Katsurada, M. 626-629
 Kawahara, Y. 586-589
 Kawai, C. 208-216
 Kawamura, M. 357-364
 Kawarabayasi, Y. 217-224, 630-633
 Kawashima, K. 517-523
 Kawashima, S. 555-558
 Kawasumi, M. 104-120, 543-554
 Kawazoye, S. 534-537
 Keno, Y. 399-406
 Kim, D. N. 474-480, 480-481, 559-561
 Kim, H.-S. 578-585
 Kino, T. 571-574
 Kinukawa, N. 494-497
 Kishi, Y. 383-392
 Kishikawa, H. 40-55
 Kishino, B. 429-439
 Kita, T. 294-300, 541-542
 Kobayashi, M. 104-120
 Köchl, S. 301-311
 Kodama, T. 226-238, 238-239
 Koga, N. 429-439
 Koide, M. 586-589
 Koizumi, J. 333-341
 Kojima, S. 429-439
 Komine, Y. 524-525
 Korenaga, R. 148-156
 Kosaka, C. 171-175, 491-493, 508-509,
 538-540, 590-591
 Kosanuki, A. 74-85
 Koyama, N. 575-577
 Kozaki, K. 530-533
 Kraft, H. G. 301-311
 Krushinsky, A. V. 12-37
 Kudryk, B. J. 461-471

Kumabashiri, I. 394-398
 Kume, N. 122-131, 541-542
 Kuro-o, M. 578-585
 Kuroda, R. 555-558
 Kuzuya, F. 510-513
 Kwitrovich, P. O. 216, 224, 238, 292, 300,
 311, 313-330, 331-332, 417, 440, 446

Lal, R. 86-102
 Latsis, R. V. 12-37
 Leight, M. A. 264-275
 Libby, P. 37-38, 121, 158-168, 168-170, 207,
 365, 472, 480, 501-507, 526-529
 Lingenhel, A. 301-311
 Liu, P.-M. 494-497
 Loskutoff, D. J. 131, 177-183, 183-184, 192,
 473

Mabuchi, H. 333-341, 341
 Makino, K. 603-605
 Makita, T. 383-392, 640-644
 Manabe, I. 578-585
 Marutsuka, K. 74-85
 Maruyama, Y. 630-633
 Mastrangelo, A. 474-480, 559-561
 Masuda, J. 171-175, 491-493, 508-509,
 538-540, 590-591
 Matsuda, T. 183, 394-398, 398
 Matsumoto, A. 226-238
 Matsumura, S. 534-537
 Matsuo, H. 517-523
 Matsuse, T. 530-533
 Matsushita, H. 333-341
 Matsuzawa, Y. 399-406, 406, 599-602,
 606-608
 Mayes, P. A. 240-262, 263
 Mindham, M. A. 240-262
 Mitsumata, M. 104-120, 543-554
 Miyasaka, M. 148-156
 Miyazaki, T. 517-523
 Mori, M. 277-281, 524-525
 Mori, T. 226-238
 Morisaka, N. 575-577
 Morishita, E. 394-398
 Morita, I. 133-147
 Moriuchi, M. 494-497
 Morohoshi, M. 562-570, 595-598
 Mulligan, R. C. 367-381
 Murakoshi, S. 626-629
 Muramatsu, M. 530-533
 Murota, S. 133-147, 147
 Muszynski, M. 501-507

Nagai, R. 578-585
 Nagano, Y. 294-300
 Naito, M. 226-238

Nakagawa, K. 185-192
 Nakajima, K. 595-598
 Nakamura, H. 226-238, 441-446, 446, 626-629
 Nakamura, T. 399-406
 Nakashima, Y. 514-516
 Nakayama, I. 586-589
 Namoto, M. 185-192
 Niezabitowski, P. 194-206
 Nishi, E. 541-542
 Nishiwaki, M. 441-446, 626-629
 Noma, A. 603-605
 Nozaki, S. 599-602
 Numano, F. xiii, 6, 170, 383-392, 393, 562-570, 595-598

Ochi, H. 541-542
 Ogata, J. 171-175, 491-493, 508-509, 538-540, 590-591
 Ohashi, Y. 555-558
 Ohno, T. 517-523
 Onsuga, J. 357-364
 Okano, M. 104-120
 Orimo, A. 530-533, 592-594
 Orimo, H. 447-460, 530-533, 592-594
 Ouchi, Y. 447-460, 530-533, 592-594

Pirich, C. 613-621
 Pollefeyt, S. 367-381
 Poulin, D. 407-417
 Pravastatin Restenosis Trial Study Group 208-216
 Prescott, M. F. 38, 169, 238, 283-292, 292-293, 331, 341, 393

Rapacz, J. 283-292
 Resnick, N. 122-131
 Robertson, A. L. 55, 57-72, 72-73, 120
 Robotewskyj, A. 86-102
 Romanov, Y. A. 12-37
 Ross, J. S. 474-480, 559-561
 Ross, R. 1-4, 5-6, 10, 38, 132, 147, 192, 238-239, 276, 281, 418, 427-428

Sadi, A. M. 514-516
 Saito, M. 394-398
 Saito, S. 494-497
 Saito, Y. 7-10, 10-11, 575-577
 Sakai, J. 217-224
 Sakai, N. 599-602, 606-608
 Sakata, N. 609-612
 Sakurai, I. 494-497
 Sasaguri, T. 171-175, 491-493, 508-509, 538-540, 590-591
 Sato, R. 524-525
 Sato, T. 630-633

Sato, Y. 74-85
 Sawamura, F. 637-639
 Scanu, A. M. 603-605
 Schmee, J. 474-480
 Schwartz, D. 526-529
 Seiffert, D. 177-183
 Sethi, S. 474-480
 Sheikh, A. 494-497
 Shige, H. 441-446
 Shima, K. 277-281
 Shimada, M. 357-364
 Shimajiri, S. 514-516
 Shimokado, K. 102, 171-175, 175-176, 491-493, 508-509, 538-540, 590-591
 Shimokama, T. 40-55
 Shimokata, H. 510-513
 Shimomura, I. 399-406
 Shindo, J. 630-633
 Shiomi, M. 630-633
 Simon-Morrissey, E. 501-507
 Sinzinger, H. 613-621
 Smirnov, V. N. 12-37, 37-39, 102, 224, 366, 418, 440
 Soboleva, E. L. 12-37
 St. Clair, R. W. 5-6, 224, 264-275, 276, 355, 365, 428
 Stein, R. J. 57-72
 Stergiopoulos, K. 447-460
 Sueishi, K. 185-192, 192-193
 Suematsu, M. 555-558
 Sukhova, G. K. 501-507, 526-529
 Sumiyoshi, A. 74-85, 85
 Sunaga, T. 534-537
 Suzuki, A. 526-529, 534-537
 Suzuki, T. 534-537
 Swies, J. 194-206

Tabata, R. E. 447-460
 Takada, Y. 148-156
 Takahashi, K. 226-238
 Takahashi, S. 217-224, 630-633
 Takamiya, M. 429-439
 Takano, T. 277-281, 281-282, 524-525
 Takashima, T. 534-537
 Takebayashi, S. 609-612
 Takei, H. 514-516
 Takeshita, A. 622-625
 Tamamoto, T. 514-516
 Tamura, M. 595-598
 Tamura, Y. 571-574
 Tanaka, A. 595-598
 Tanaka, H. 471-473, 526-529
 Tanaka, K. 121
 Tanaka, S. 517-523
 Tararak, E. M. 12-37
 Tatami, R. 429-439
 Thomas, W. A. 474-480

- Tian, S.-F. 534-537
 Toda, S. 534-537
 Toda, T. 514-516
 Tohjima, T. 543-554
 Tokinaga, K. 571-574
 Tokunaga, K. 399-406, 606-608
 Tokunaga, O. 498-500
 Tomita, I. 637-639
 Tomita, T. 637-639
 Tomiyasu, K. 626-629
 Toyama-Sorimachi, N. 148-156
 Toyota, Y. 429-439
 Trommsdorff, M. 301-311
 Tsuboi, H. 148-156
 Tsuda, T. 586-589
 Tsuneyoshi, A. 74-85
 Tsushima, M. 429-439
- U**chimura, I. 562-570, 595-598
 Uetsuka, R. 637-639
 Ueyama, K. 294-300
 Uotani, C. 394-398
 Utermann, G. 293, 301-311, 311-312, 331-332, 341
- V**an Aken, B. E. 177-183
 Von Linden-Reed, J. 283-292
- W**ada, Y. 226-238
 Wakabayashi, Y. 133-147
 Wakimoto, N. 626-629
 Wang, S. 104-120
- Watanabe, M. 578-585
 Watanabe, R. 383-392
 Watanabe, T. 40-55, 55-56
 Watanabe, Y. 357-364
 Wissler, R. W. 37, 56, 73, 85, 169, 183, 275, 293, 300, 311-312, 365, 471, 645-650
 Wvns, S. 367-381
- Y**agi, K. 333-341
 Yamada, N. 357-364, 364-366
 Yamaguchi, H. 578-585
 Yamamoto, A. 429-439, 439-440
 Yamamoto, M. 634-636
 Yamamoto, T. 217-224, 224-225, 630-633
 Yamashita, S. 599-602, 606-608
 Yamazaki, M. 394-398
 Yancey, P. G. 264-275
 Yazaki, Y. 226-238, 357-364, 578-585
 Yokode, M. 225, 294-300, 300
 Yokota, T. 171-175
 Yokoyama, K. 630-633
 Yokoyama, M. 555-558, 586-589
 Yoshida, S. 571-574, 575-577
 Yoshida, Y. 104-120, 120-121, 543-554, 599-602
 Yoshinari, M. 634-636
 Yui, K. 595-598
 Yui, Y. 208-216, 216
 Yutani, C. 491-493
- Z**en, K. 171-175, 491-493, 508-509, 538-540, 590-591
 Zhao, X.-Q. 407-417

Subject Index

- A**
A. See Arachidonic acid
ACAT. See Acyl-CoA:cholesterol acyltransferase
ACE inhibitors. See Angiotensin-converting-enzyme inhibitors
Activated platelets
 cytotoxicity of, 383-385
 and EC dysfunction, 385-387
 and PDGF release, 78
 and thrombus formation, 383
Activin, 530-531
Acute phase proteins, 466, 562
Acyl-CoA:cholesterol acyltransferase (ACAT), 195. *See also* Cholesteryl ester hydrolase
 in cholesterol metabolism, 264, 270-271, 357, 359-363
 heparin inhibition of, 636
 M-CSF and, 360
Adhesion molecules, 148, 150-153, 155. *See also* ELAMs; ICAM-1; VCAM-1
 and EC injury, 136-138, 144
 in leukocyte-endothelial adhesion, 123-126, 133-134
 in peroxide production, 133-139
 signal transduction via, 144-145
 and xanthine oxidase activation, 134, 141-146
Advanced glycosylation end products (AGEs), 562, 564, 566-569
AGEs. *See* Advanced glycosylation end products
Alcohol consumption, and lipoprotein levels, 626-629
Amaurosis fugax, 491
American Heart Association (AHA) Phase II diet, 343
 and atherosclerosis, 313
 and CHD, 295
 and cholesterol efflux, 295
 and PGI₂ synthesis, 194
Aneurysm, in atherosclerosis, 163
Angina pectoris, TXA₂ in, 195
Angioplasty. *See* Percutaneous transluminal coronary angioplasty
Angiotensin-converting-enzyme (ACE) inhibitors, 421-423
 and restenosis, 420-421
Angiotensin II, 187
ANP. *See* Natriuretic peptides
Anticoagulants, for restenosis, 421-422
Antiplatelet therapy
 for ischemic heart disease, 387-391
 for restenosis, 420-422
 for thrombosis, 78
Antiproliferative agents, 421-423
Apolipoprotein A (ApoA), 313
 in CAD family children, 315
 in HDL, 240-241, 247-248, 251-252
 obesity in youth and, 316
 and RCT, 251-253
Apolipoprotein(a) [Apo(a)]
 as atherosclerosis risk factor, 190
 in atherosclerotic intima, 185
 and CHD, 308-309
 immunohistological distribution of, 189
 in premature CAD, 313
Apolipoprotein B (Apo B)
 and atherosclerosis, 313
 and CAD, 283-291, 315
Apolipoprotein B (Apo B) genotype
 cholesterol levels in, 284-288, 290-291
 coronary artery stenosis in, 285-291
Apolipoprotein B-100 (Apo B-100), 595
Apolipoprotein C (apo C), 247-248, 251-252
Apolipoprotein E (Apo E), 240-241, 248, 250-252, 441, 444-445
Apolipoprotein E-containing lipoproteins, 219, 222
Apolipoproteins
 CS alteration of, 299
 in HDL, 246-248
 liver uptake of, 259
Arachidonic acid (AA), 194, 476. *See also* Eicosapentaenoic acid
 NOS inhibition by, 556-558
 and platelet aggregation, 78
Arteriosclerosis Specialized Center of Research Study, 351
Arteriosclerotic lesions, follistatin expression in, 530-532
Artery-to-artery thromboembolism, 491-493
 as negative atherosclerosis risk factor, 336-337
Aspirin (ASA)
 antiplatelet effects of, 420-421
 antithrombotic effects of, 200-201
 and hepatomegaly, 640, 642
 and monocyte-EC interaction, 560
 and peroxisome proliferation, 640-643
 and PGI₂/NO release, 199-201
 and platelet adhesion, 78
 and TXA₂ formation, 195
ATHERO-ELAM
 and atherogenesis, 125
 characterization of, 124
 expression of, 125-126
 pathophysiologic implications of, 126
ATHERO-ELAM hypothesis, 123-126

Atherogenesis

- arterial cell proliferation in, 58
- ATHERO-ELAM hypothesis of, 123-126
- cytokine influences on, 160-161
- EC inflammatory-proliferative responses and, 68-69
- hemodynamics and, 86-88
- HSV and, 57-60, 66-69
- immunologic implications in, 49-53
- leukocyte clusters and, 25
- macrophage-SM fibroproliferative response and, 2
- prelesional change and, 44
- SMC proliferation in, 313
- T lymphocyte-macrophage interaction in, 42, 44-53
- transformed cell clones and, 58-59, 66-69

Atheroma

- coagulation/fibrinolysis components in, 465-466
- cytokines in, 158
- inflammatory-proliferative responses and, 57-58
- TF in, 186-187

Atheromatous embolism, 491-493

Atheromatous plaques, 185

- T lymphocytes in, 47-49

Atherosclerosis

- apo B genotype and, 285-291
- apolipoproteins and, 190, 313, 445
- ATHERO-ELAM hypothesis, 123-126
- decreased HDL levels and, 283
- in diabetes mellitus, 562
- ECM dysregulation in, 501-506
- EC proliferative activity and, 12
- elevated LDL levels and, 283, 290
- endothelial heterogeneity and, 14-17, 32
- leukocyte adhesion in, 123-126
- M-CSF in, 357-363
- multifactorial events in, 57-58
- PDAY study, 314
- PDGF in, 8-10
- PGI₂ suppression in, 194-195
- PKC activation and, 539-540
- prevention of, 447-458
- regression of, 429-437
- response-to-injury hypothesis of, 3, 383, 538
- risk factors for, 177, 313-318
 - PIB control of, 342, 344-345, 348
 - POSCH and, 342-352
 - SMC migration and, 2, 34
 - syndrome X and, 400
 - thrombosis and, 462-463, 467-468
 - TXA₂ in, 195
 - in youth, 313-318, 328

Atherosclerotic aorta

- procoagulant properties of, 185
 - TF localization in, 186-187
- Atherosclerotic lesions, 1
- apo(a) in, 185
 - c-myc* expression in, 514-515
 - comparative evaluation of, 494-497
 - EC polymorphism and, 12
 - fatty streaks and, 41, 313
 - folistatin in, 530-532
 - macrophages in, 40-41, 47-53, 313
 - multinucleated EC increase and, 14
 - T lymphocytes in, 40-53
 - vitronectins in, 524-525
 - in youth, 313-314
 - lipid risk factors for, 313-315
 - nonlipid risk factors for, 315-318

Atherosclerotic plaque

- hypercoagulability of, 186-187
 - M-CSF roles in, 160
 - molecular characterization of, 463-464
- Atomic force microscopy (AFM), 90-95
- Atrial natriuretic peptide (ANP), 384, 517-519, 521

Baltimore Longitudinal Study of Aging (BLSA), 511

Brain infarcts, 491-493

C a²⁺ antagonists, and restenosis, 421-422

Ca²⁺ channel blockers

- antiatherogenic effect of, 195, 447
- estrogen as, 449-458
- MG²⁺ as, 448-449

Ca²⁺ levels

- activated platelets and, 384
- Ca²⁺ mobilization and, 385

CAD. *See* Coronary artery disease

cAMP-dependent kinase (A-kinase), 638-639

cAMP-elevating cytokines, 586-589

cAMP levels, vascular injury and, 384

CD. *See* Adhesion moleculesCD4+/CD8+ cells. *See* T lymphocytesCE. *See* Cholesteryl ester

Cell migration/proliferation, 2-3

CFUs. *See* Colony-forming unitsCholesterol. *See also* Lipoproteins

- liver uptake of, 254-255
- macrophage uptake of, 264-274
- metabolism of
 - ACAT in, 357, 359-360, 362-363
 - heparin and, 634-646
 - in macrophages, 357-363

Cholesterol levels

- after LDL-apheresis, 436
- apo B genotype and, 284-291

- and cancer, 483-485, 488
- and cardiovascular disease, 483-488
- dietary approach to, 319-328
- diets for. *See also* American Heart Association diet
- and disease
 - in low- vs. high-cholesterol countries, 482-488
 - preventive strategies, 485-488
 - U-shaped relationship of, 487
- and fibrinogen levels, 467
- fish oils and, 474-475
- GM-CSF and, 630-632
- and hemorrhagic stroke, 486-488
- longitudinal changes in, 510-513
- and mortality
 - from cancer, 483-485, 488
 - from cardiovascular disease, 484-485
 - J-shaped relationship for, 483-485, 487
 - noncardiovascular-noncancer, 482-488
 - non-illness-related, 484-485
- PIB and, 342, 343-345
- in Sumo wrestlers, 402
- Cholesterol Lowering Atherosclerosis Study (CLAS), 344, 351, 415
- Cholesterol-lowering therapy, 622-625
- Cholesterol reverse transport. *See* Reverse cholesterol transport
- Cholesterol transport
 - from spleen to blood, 245-246
 - from spleen to HDL, 246-249
- Cholesterol transport disorders, 333-340
- Cholesteryl ester (CE)
 - estrogen-enhanced hydrolysis of, 638-639
 - in RCT, 601-602, 606
 - VHDL and, 607-608
- Cholesteryl ester (CE) hydrolase. *See also* Acyl-CoA:cholesterol transferase
 - in cholesterol metabolism, 357, 359-360, 362-363
- Cholesteryl ester (CE) metabolism, 637-639
- Cholesteryl ester transfer protein (CETP)
 - function of, 333-334, 599, 602, 606
 - in HDL-to-VHDL transformation, 608
 - mutant genes of, 339
 - in RCT, 606-608
- Cholesteryl ester transfer protein (CETP) deficiency
 - alcohol intake and, 626-629
 - and atherosclerosis incidence, 336
 - and CHD, 339-340
 - in familial hyper-HDL-cholesterolemia, 336-340
 - gene mutations in, 599
 - and HALP, 599
 - HDL levels in, 601-602, 606
 - HTGL activities in, 599-602
 - and hypo-LDL-cholesterolemia, 340
 - lipoprotein abnormalities in, 599, 606
 - and longevity syndrome, 336-337
 - LPL activities in, 600-602
 - and RCT impairment, 601-602
- Chylomicron remnants, 334, 441-445
- Cigarette-smoke-modified HDL (CS-HDL), 298-299
- Cigarette-smoke-modified LDL (CS-LDL)
 - characteristics of, 295-296
 - and macrophage foam cell transformation, 296-299
- Cigarette smoking
 - as atherosclerosis risk factor, 343
 - and CAD, 28, 313, 318
 - and fibrinogen level, 467
 - and IHD risk, 467
- CMV. *See* Cytomegalovirus
- C-myc expression, in atherosclerotic lesions, 514-515
- CNP. *See* Natriuretic peptides
- Collagens
 - in atheroma, 163
 - oxLDL binding with, 609-611
 - in vascular ECM, 163
- Colony-forming units (CFUs), 33, 35
 - in early atherogenesis stages, 25-30
 - hypercholesterolemia and, 32
- Colony-stimulating factor (CSF), 33
- Coronary artery bypass graft (CABG), 333
 - in POSCH, 344, 346-348, 352
- Coronary artery disease (CAD). *See also* Premature coronary artery disease
 - apo B levels and, 283-291, 315
 - in children of CAD parent, 315
 - cholesterol blood levels and, 314-318
 - dyslipidemias associated with, 283-284
 - dyslipoproteinemias in, 320-323
 - fat distribution in, 400
 - FCHL gene and, 315
 - HDL levels in, 315
 - inherited dyslipidemia gene in, 315
 - LDL levels and, 283, 290
 - NCEP dietary recommendations, 319
 - postprandial hyperlipemia and, 441-445
 - risk factors for, 328
- Coronary heart disease (CHD)
 - apo(a) polymorphism and, 308-309
 - FH-CETP deficiency combination and, 339-340
 - HDL and, 295, 599
 - Lp(a) concentrations and, 301
 - mortality in POSCH, 344-346, 350
 - PIB and, 342
 - RLP levels in, 595-598
- Coronary stenosis changes. *See* Familial Atherosclerosis Treatment Study

CRT. *See* Reverse cholesterol transport
 CS-LDL. *See* Cigarette-smoke-modified LDL
 C-type natriuretic peptide (CNP), 517-523
 Cyclins, 538-540
 Cytokines
 in atherogenesis, 158-165
 immunologic implications of, 50-53, 69
 and atheroma progression, 57-58, 160-161
 in collagen synthesis regulation, 163
 and cytokine/growth factor genes, 159-160
 foam cell formation and, 2
 intimal expression of, 44, 46
 and leukocyte adhesion molecules, 123-125, 158-159
 in NOS induction, 586-589
 and prelesional changes, 44
 and pro- and antiatherogenic actions, 160-161, 164-165
 and vascular cell-blood compatibility, 161-162
 and vascular ECM homeostasis, 162-164
 and vasomotor arterial tone, 161
 Cytomegalovirus (CMV), 58, 67

DAG. *See* 1,2-Diacylglycerol
 Deadly quartet, 400
 Diabetes mellitus. *See also*
 Insulin-dependent diabetes mellitus
 as atherosclerosis risk factor, 343
 atherosclerotic pathogenesis in, 562
 and CAD, 313, 318, 328
 hyperfibrinogenemia in, 568-569
 1,2-Diacylglycerol (DAG), 2, 538-540
 Diarrhea, as PIB side effect, 345, 348
 Diet and Reinfarction Trial (DART), 467
 Dyslipidemia. *See also* Hypercholesterolemia
 and CAD, 283-284
 in CAD family children, 315, 318
 genetic determinants of, 283, 315
 Dyslipoproteinemia, 314, 325-328

ECM. *See* Extracellular matrix
 Ectasia, 163
 Eicosapentaenoic acid (EPA), 467, 474-479
 ELAM. *See* Endothelial-leukocyte adhesion molecules; E-selectin
 Endothelial cells (ECs). *See also* Human aortic endothelial cells; Human umbilical vein endothelial cells
 abluminal surface features, 95-100
 activated platelet effects on, 383-387
 adhesion properties of
 GMP-140 and, 18-19
 and leukocyte binding, 22-24
 balloon injury activation of, 526-528
 cAMP changes in, 383-384
 dysfunction of, 385-388

GAG synthesis in, 543-552
 in high shear-stress regions, 106
 injury to
 adhesion molecules role in, 133-134, 136-138, 144
 oxidative stress and, 133-146
 in low shear-stress regions, 105-106, 114, 116
 luminal surface features, 90-95
 mechanotransduction at, 88-89
 morphological heterogeneity of, 12, 14-17
 proliferation
 and atherosclerosis, 12, 14, 32-33
 in HP and LP zones, 15-16, 32-33
 PKC pathway inhibition of, 538-540
 and SMC phenotype change, 7, 9
 tension and, 89-90
 Endothelial dysfunction
 and atherosclerosis, 122
 hemodynamic induction of, 126-128
 oxidative stress and, 133-146
 SSRE in, 123, 128, 155
 Endothelial-leukocyte adhesion molecules (ELAMs), 123-124
 and early atherosclerotic lesions, 124-125
 in ECs, 498-500
 EPA effects on, 478-479
 IL-1 induction of, 475
 Endothelial permeability
 and atherosclerosis, 114, 116, 118-119
 for macromolecules, 106
 Endothelium
 as complex organ, 122
 and leukocyte-selective adhesion, 19, 22-25, 123-126. *See also* ELAMs
 as pathophysiologic milieu integrator, 129
 Endothelium-dependent vasodilation, 622-625
 EPA. *See* Eicosapentaenoic acid
 E-selectin (ELAM-1), 124-125, 154, 541-542
 Estrogen
 antiatherogenic effects of, 449-458, 637
 in CE metabolism, 637-639
 Estrogen receptor (ER), in VSMC, 592-594
 Extracellular matrix (ECM)
 dysregulation, 501-506
 organization, 534-537

Factor VII, 394-396, 398
 Familial Atherosclerosis Treatment Study (FATS), 351
 coronary lesion change, 410-411
 lesion progression/regression, 413-414
 lipid-altering strategies in, 407-408
 results, 415-417
 Familial combined hyperlipidemia (FCHL), 315, 324

- Familial hyperalphaproteinemia, 336-337, 339. *See also* Familial hyper-HDL-cholesterolemia
- Familial hypercholesterolemia (FH), 33, 226
apheresis therapy for, 430-435
and atherosclerosis, 283-291
and CAD risk, 314-315
genetic basis of, 324
in LARS, 435-436
LDL-receptor abnormalities in, 333-336
and premature CAD, 324
- Familial hyper-HDL-cholesterolemia, 333, 336, 339. *See also* Familial hyperalphaproteinemia
- Familial hypertriglyceridemia (FHT), 325
- Fatty acids
in fish oils, 474-476
and monocyte adhesion, 476-479
n-3 fatty acids. *See* Eicosapentaenoic acid
n-6 fatty acids. *See* Arachidonic acid
- Fatty streaks, 44-47
and atherosclerotic lesions, 41
cholesterol levels and, 314
as earliest atherosclerotic lesion, 313
foam cells and, 123
ganglioside deposition in, 277-281
TF expression in, 187-188, 190
- FCHL. *See* Familial combined hyperlipidemia
- FHT. *See* Familial hypertriglyceridemia
- Fibrin
in atherosclerotic plaques, 463-465
immunohistological distribution of, 189-190
- Fibrinogen
as acute phase protein, 562
in atherosclerosis, 461-468
- Fibrinogen levels. *See also* Hyperfibrinogenemia
as cardiovascular disease risk factor, 562, 567
in diabetes, 568-569
fish oils and, 467
IL-6 levels and, 562, 568-569
smoking and, 467
- Fibrinolysis, 177
Lp(a) and, 394
in tissue remodeling, 380
- Fibrinolytic system, 177-178
fibrinolytic gene expression, 178-180
PAI and, 367-368, 394
- Fibroblast growth factor (FGF), 420
- Fish oils. *See also* Arachidonic acid; Eicosapentaenoic acid
and cholesterol levels, 474-475, 479
and fibrinogen levels, 467
hypothrombotic/hypospasmic effects of, 474
and IHD mortality, 479
and monocyte-EC interactions, 475-479
in restenosis prevention, 421-422
- Foam cells
in atheromatous plaques, 47-48
and fatty streak formation, 41, 44-47, 123
formation of
apo E in, 445
CS-LDL and, 295-298
SCP₂ and, 571-574
macrophage transformation and, 41, 44, 123
TF expression in, 186-187
Follistatin expression, 530-532
- G** AG. *See* Glycosaminoglycan
- Gangliosides. *See* Asialo GM2 in fatty streaks, 277-281
- GC. *See* Guanyl cyclases
- Glucose, and cytokine production, 562-564, 568-569
- Glycosaminoglycan (GAG) synthesis, 543-552
- GM2. *See* Gangliosides
- GM-CSF. *See* Granulocyte-macrophage colony-stimulating factor
- GMP-140, 154
in EC-leukocyte interactions, 24
expression
under hemodynamic flow, 19-21
in human aortic endothelium, 18-19
- Granulocyte-macrophage colony-stimulating factor (GM-CSF), 630-632
- Guanyl cyclases (GC)
as CNP receptor, 517
in injured arteries, 519, 522-523
as NP receptors, 517, 519
SMC expression of, 518
- H** AEC. *See* Human aortic endothelial cells
- HALP. *See* Hyperalphalipoproteinemia
- HB-EGF. *See* Heparin-binding EGF-like growth factor
- HC. *See* Hypercholesterolemia
- Helsinki Heart Study, 351
- Hematopoietic colony-forming units (CFUs) and hypercholesterolemia, 32
and precursor cells with stromal potencies, 25-30
- Hemodynamics
and atherogenesis localization, 86-88
and cell adhesion, 97-100
and GMP-140 expression, 19
shear stress

- and atherosclerosis, 86–88
 - distribution, 90–95
 - Hemorrhagic stroke, 486–488
 - Hemostasis, PAI-1 in, 368, 375
 - Heparin, 634–636
 - Heparin-binding EGF-like growth factor (HB-EGF)
 - and atherosclerotic lesions, 123
 - in fibroproliferative response, 2
 - Hepatic lipase (HL), 626, 628
 - Hepatic triglyceride lipase (HTGL), 599
 - activities of, 600–602
 - in VLDL formation, 607
 - Hepatomegaly/hepatic carcinogenesis, 640
 - Herpes simplex virus (HSV), 58–59, 66–68
 - Herpes viruses, 58
 - High blood pressure, and CAD, 313, 316–317, 328
 - High-density lipoprotein (HDL)
 - antiatherogenic effect of, 599
 - apolipoprotein composition of, 240–241, 251–252
 - liver uptake of, 253–259
 - in RCT, 240–241, 246–254, 257–261
 - High-density lipoprotein cholesterol (HDL-C)
 - alcohol intake and, 627–629
 - CETP deficiency and, 628
 - High-density lipoprotein (HDL) levels
 - in CAD-family children, 315
 - in CETP-deficient patients, 599, 602
 - fish oils and, 422
 - vs. LDL/VLDL levels, 314
 - NCEP definitions, 315
 - and RCT, 249–261
 - High-probability of atherosclerosis zones (HP zones), 12, 15–16, 32–33
 - High shear-stress regions
 - and atherogenesis, 106
 - EC characteristics in, 106
 - lipid deposition at, 104, 111–112
 - Z/M tight junction ratios in, 111, 113, 119
 - HL. *See* Hepatic lipase
 - 15-HPODE. *See* Lipoperoxides
 - HSV. *See* Herpes simplex virus
 - HTGL. *See* Hepatic triglyceride lipase
 - Human aortic endothelial cells (HAECs), 15–25
 - Human umbilical vein endothelial cells (HUVECs), 18, 22–25
 - HUVECs. *See* Human umbilical vein endothelial cells
 - Hyperalphalipoproteinemia (HALP), 599–602. *See also* Familial hyperalphalipoproteinemia
 - Hypercholesterolemia (HC). *See also* Familial hypercholesterolemia; Polygenic hypercholesterolemia
 - and atherogenesis, 40–41, 44–47
 - and CAD, 283–291
 - EC proliferation in, 33
 - endothelium-dependent vasodilation impairment in, 622–625
 - LDL-apheresis therapy for, 429–437. *See also* LDL-apheresis regression study
 - LDL receptors and, 217
 - Hyperemia, 197–199
 - Hyperfibrinogenemia, 562, 568–569
 - Hyperglycemia, 562, 568–569
 - Hyperlipidemia. *See* Hypercholesterolemia
 - Hypertension
 - and arterial wall thickening, 534–537
 - as atherosclerosis risk factor, 343
 - vascular abnormalities in, 317
 - Hypertriglyceridemia, 315
 - Hypoalpha, 325
- I** CAM-1. *See* Intercellular adhesion molecule-1
- IDDM. *See* Insulin-dependent diabetes mellitus
- IFN γ . *See* Interferon
- IGF-1. *See* Insulin-like growth factor
- IL. *See* Interleukins
- Inositol triphosphate (IP $_3$), 2, 385
- Insulin-dependent diabetes mellitus (IDDM), 318
- Insulin-like growth factor (IGF-1), 2
- Integrin receptor (VLA-4), 124–125
- Intercellular adhesion molecule-1 (ICAM-1), 153, 155
 - and CD11/CD18 binding, 124, 134, 136–137, 141
 - cytokines and, 158–159, 526, 528
 - and EC injury, 137–139, 144, 146, 475
 - in ECs, 498–499
 - EPA effects on, 478–479
 - giant ECs and, 33
 - in intracellular signal transduction, 144–145
 - lyso-PC up-regulation of, 541–542
 - and xanthine oxidase activation, 134, 141
- Interferon γ (IFN γ), 2, 50, 161, 279
 - and atherosclerotic lesions, 123
 - NOS induction by, 586–587
- Interleukin-1 (IL-1), 48, 50, 187
 - in atheroma, 466
 - and atherosclerotic lesions, 123
 - and cytokine expression, 160
 - fatty streak expression of, 46
 - fish oils and, 475
 - and ICAM expression, 158–159

- and IL-2 production, 51
 - intimal expression of, 44
 - in macrophage-SMC fibroproliferative response, 2
 - MMPs induction by, 501, 503-506
 - NOS induction by, 586-587
 - and PDGF production, 159
 - and SMC phenotypic change, 8-9
 - and vascular wall injury, 526, 528
 - Interleukin-4 (IL-4), 123
 - Interleukin-6 (IL-6), 466, 526, 562, 564, 566, 568-569
 - Interleukin-8 (IL-8), 526
 - Intermediate-density lipoprotein (IDL), 217, 334
 - Intimal hyperplasia, 9
 - platelets and, 74-84
 - in post-PTCA restenosis, 420
 - Ischemic heart disease (IHD)
 - antiplatelet therapy for, 387-391
 - Ca²⁺/Mg²⁺ dietary ratio and, 448
 - fish oil effect on, 479
 - PGI₂ deficiency in, 195
 - smoking and, 467
 - treadmill exercise test effects in, 389-391
 - visceral fat obesity in, 405
- J**apan National Survey for Coronary Heart Disease, 510-511
- L**ARS. *See* LDL-apheresis regression study
- LCAT. *See* Lecithin:cholesterol acyltransferase
- LDL. *See* Low-density lipoprotein
- LDL-apheresis, 430-437
- LDL-apheresis regression study (LARS), 435-436
- Lecithin:cholesterol acyltransferase (LCAT), 333-334, 602, 606, 608
- Leukocyte adhesion molecules. *See also* ELAM
- cytokine regulation of, 158-159
- Leukocyte-endothelium adhesion
- ATHERO-ELAMs and, 123-125
 - in atherosclerotic lesions, 123-126, 499-500
 - and EC injury, 133-146
 - NSAID inhibition of, 560
 - xanthine oxidase and, 140-141, 144
- Leukocytes. *See also* Macrophages;
- Monocytes; T lymphocytes
- endothelium interaction with, 19-20, 22-25
- hyperadhesiveness of, 122
 - intimal infiltration by, 13-14
 - PMA-activated, 133-146
- Lifestyle Heart Trial, 467
- Lipid deposition patterns, 110-112, 118-119
- Lipids, 314-315
- Liperoxides, 194-195
- Lipoprotein(a) [Lp(a)], 603. *See also* Apolipoprotein(a)
- and apo(a) density relationship, 603-605
 - in atherosclerotic plaques, 466
 - and CAD, 313, 328
 - in CAD family children, 315
 - and CHD, 301
 - and fibrinolysis, 394
 - genetic architecture
 - apo(a) in, 301-304, 307-308
 - K 37 polymorphism, 305-306
 - sib-pair linkage analysis, 304
- Lipoprotein lipase (LPL), 600-601
- Lipoproteins. *See also* High-density lipoprotein; Intermediate-density lipoprotein; Low-density lipoprotein; Very low density lipoprotein
- and chemotactic factors, 1
 - CS modification of, 294-295
 - and premature CAD, 314-315
- Liver, in RCT, 253-261
- Longevity syndrome, 336-337
- Low-density lipoprotein (LDL)
- in atherogenesis, 125-126
 - and atherosclerosis, 313, 336-337
 - and CAD, 283, 290
 - CS modification of. *See* Cigarette-smoke-modified LDL
 - as liperoxides carrier, 194
 - POSCH study, 342-352
 - in TF induction, 187
 - uptake of, 240
 - vascular uptake of, 613-620
- Low-density lipoprotein (LDL) levels
- in CAD family children, 315
 - fish oils and, 422, 474-475, 479
 - NCEP definitions, 315
- Low-density lipoprotein (LDL) receptors, 217-219, 226. *See also* Very low density lipoprotein receptors
- Low-probability of atherosclerosis zones (LP zones), 12, 16
- Low shear stress regions, 104-106, 111-113, 119
- Lpb genes. *See* Apolipoprotein B genotype
- LPC. *See* Lysophosphatidylcholine
- Lysophosphatidylcholine (LPC), 540-542, 556-558

Macrophage chemoattractant and activating factor. *See* Monocyte chemoattractant protein-1

- Macrophage colony-stimulating factor (M-CSF), 125, 630-632
 in atherosclerosis, 357-363
 and cholesterol efflux, 360-363
 in fibroproliferative response, 2
 in lipoprotein metabolism, 357, 359-360
 and macrophage survival, 160
 and vascular wall injury, 526
 Macrophages. *See also* Leukocytes;
 Monocytes; T
 lymphocyte/macrophage interaction
 in atherogenesis, 40-41, 49-53
 in atherosclerotic lesions, 313
 cholesterol metabolism in, 357-363
 cholesterol uptake by, 264-274
 and chylomicron remnants, 444-445
 in foam cell formation, 41, 44, 123
 CS-LDL and, 295-298
 SMC fibroproliferative response, 2
 TF expression by, 187
 uPA production in, 376-377
 Macrophage scavenger receptors (MSR),
 226-236
 Macular-type tight junctions, 108, 111-114,
 118-119
 Major histocompatibility complex (MHC),
 50-51
 MAP kinase system. *See* Mitogen-activated
 protein kinase
 Marek disease, 66
 MARS. *See* Mevinolin Atherosclerosis
 Regression Study
 Matrix metalloproteinases (MMPs), 163-164,
 501, 503-506
 MCP-1. *See* Monocyte chemoattractant
 protein-1
 M-CSF. *See* Macrophage colony-stimulating
 factor
 Mevinolin Atherosclerosis Regression Study
 (MARS), 351
 Mg²⁺, antiatherogenic effect of, 448-449
 MI. *See* Myocardial infarction
 Mitogen-activated protein (MAP) kinase
 system, 2-3
 MMP. *See* Matrix metalloproteinases
 Monocyte chemoattractant protein-1
 (MCP-1), 125-126
 in atherosclerotic plaques, 466
 as chemokine, 159-160
 in hypercholesterolemia, 33
 IL-1 regulation of, 160, 475
 Monocyte-endothelial cell adhesion. *See*
 Leukocyte-endothelium adhesion
 Monocytes. *See* Leukocytes; Macrophages; T
 lymphocytes
 MSR. *See* Macrophage scavenger receptors
 Myocardial infarction (MI), 315, 559-561
 Myosin heavy chain (MHC) isoforms,
 579-580
- N**ational Cardiovascular Center, 491-492
 National Cholesterol Education Program
 (NCEP)
 Expert Panel on Blood Cholesterol Levels
 in Children and Adults, 315, 319,
 350-351
 National Heart, Lung, and Blood Institute
 (NHLBI), 350-351
 N-CEase. *See* Neutral cholesterol esterase
 NCEP. *See* National Cholesterol Education
 Program
 Nephrolithiasis, 345, 348
 Neutral cholesterol esterase (N-CEase)
 activity, 638-639
 Nitric oxide (NO)
 atherogenesis and, 194
 biological actions of, 587, 589
 and hypercholesterolemia, 195-196
 for restenosis, 423
 and SMC responsiveness, 195
 in thrombolytic responses, 199-203
 turnover, 196-198, 203
 as vascular tone regulator, 161, 555
 Nitric oxide synthase (NOS)
 activation/inhibition of, 555-558
 cAMP-induced expression of, 586-589
 Nonsteroidal antiinflammatory drugs
 (NSAIDs), 559. *See also* Aspirin;
 Sodium salicylate
- O**besity. *See also* Visceral fat obesity
 as atherosclerosis risk factor, 315-316, 343
 and CAD, 313, 315-316, 328
 classification of, 399
 vs. lipid changes, 511-513
 Omega-3 fatty acids. *See* Fish oils
 Oxidative stress, and EC injury, 133-146
 Oxidized LDL (OxLDL), collagen-binding
 activity of, 609-611
- P**AI-1. *See* Plasminogen activator inhibitor
 Partial ileal bypass (PIB), 342-345, 348
 Pathological Determinants of
 Atherosclerosis in Youth (PDAY)
 study, 314
 PDGF. *See* Platelet-derived growth factor
 Percutaneous transluminal coronary
 angioplasty (PTCA)
 in FATS trial, 408-416
 POSCH and, 344, 348, 352
 restenosis rates after, 77-78, 208, 414
 with lovastatin treatment, 214, 414
 with pravastatin treatment, 209-215

- Peripheral vascular disease, 348
Peroxisomes, aspirin and, 640-643
PGI₂. *See* Prostacyclin
Phorbol myristate acetate (PMA), 134-136, 478, 538-540
Phosphatidylcholine (PC), 556-558
Phosphoinositide biphosphate (PIP₃), 2
Phospholipase C γ (PLC γ), 2
Physical inactivity
 and atherosclerosis, 318
 and CAD, 318, 328
PIB. *See* Partial ileal bypass
PKT. *See* Protein tyrosine kinase
Plaques. *See also* Atheromatous plaque;
 Atherosclerotic lesions
 classification of, 495-497
Plasmapheresis. *See* LDL-apheresis
Plasminogen activator inhibitor-1 (PAI-1), 127, 196
 and arteriosclerosis, 394-398
 and atherosclerosis, 177, 466
 binding proteins and, 180
 biological roles of, 377-380
 deficiency of, 369-370
 in diabetes mellitus, 396-397
 and fibrinolysis, 394
 and fibrinolytic system, 367
 in gonadotropin-induced ovulation, 368
 in hemostasis, 368, 375
 in ischemic heart disease, 389-391
 in normal and atherosclerotic vascular tissues, 178-179
 and PA activity, 178
 Vn localization of, 189
Plasminogen activators (PAs), 178-179
Platelet activation, 185
Platelet adhesion
 in atherosclerosis, 77
 and intimal thickening, 74-84
 macrophages and, 383
 and restenosis, 420
Platelet-derived growth factor (PDGF), 2, 127-128
 in atherosclerosis, 78-79
 and atherosclerotic lesions, 123
 in atherosclerotic plaques, 466
 expression of, 514-515
 in inositol phosphate pathway activation, 3
 in macrophage-SMC fibroproliferative response, 2
 in MAP kinase system activation, 2-3
 in post-PTCA restenosis, 420
 and SMC binding, 79-84
 and SMC phenotype change, 8-10
 in TF expression, 87
 and vascular SMC proliferation, 78
PMA. *See* Phorbol myristate acetate
Polygenic hypercholesterolemia, 325
Polyunsaturated fatty acid (PUFA)
 in fish oils, 475
 and LDL oxidation, 474
POSCH. *See* Program on the Surgical Control of the Hyperlipidemias
Post-PTCA restenosis, 77-78, 208
 cholesterol reduction and, 210-211, 213, 215
 in FATS trial, 407-416
 lipid profile in, 212
 pravastatin trial, 208-215
 prevention of, 419-426
 rate of, 209-211
 residual stenosis and, 213, 215
 RLP and, 595-598
Pravastatin
 and endothelium-dependent vasodilation, 622-625
 trial, 208-215
Premature coronary artery disease (CAD)
 dyslipidemias in, 314-315, 318-319, 321-324
 dyslipoproteinemia treatment, 325-328
 high risk assessment for, 320-323
 hypoalpha and, 325
 interpretation guidelines for, 320
 LDL production disorders and, 324
 polygenic hypercholesterolemia and, 325
 risk factors for, 315-318, 328
 safety of intervention in, 326-327
 weight control/aerobic exercise in, 326
Program on the Surgical Control of the Hyperlipidemias (POSCH)
 and CABG, 344, 346-348, 352
 and CHD mortality, 343, 345-346, 350-352
 and nonfatal myocardial infarction, 346-347, 349, 351-352
 and overall mortality, 343, 345-346, 350, 352
 and peripheral vascular disease, 348
 and PIB, 342, 344-345, 348, 352
 women in, 350, 352
Prostacyclin (PGI₂), 127, 465
 age-related decline in, 195
 analogues of
 actions of, 195
 and intimal thickening, 78
 antiatherosclerotic function of, 194-196
 atherogenic suppression of, 194-196
 deficiency of, 195
 LDL-influenced release of, 194
 n-3 fatty acids and, 475
 and NO interaction, 201-203
 in restenosis prevention, 420
 in thrombolytic response, 199-201

- Protein kinase C (PKC)
 and EC proliferation, 538–540
 in ICAM-1 up-regulation, 541–542
 isoforms of, 590–591
 in MCP-1 gene expression, 508–509
- Protein tyrosine kinase (PTK)
 in MCP-1 gene expression, 508–509
 and SMC growth factor signal transduction, 173
 and SMC proliferation/locomotion, 171
- Protein tyrosine kinase (PTK) inhibitors,
 171–172
 and cytoskeletal reorganization, 173–174
 and PDGF-induced SMC chemotaxis,
 172–173
- PUFA. *See* Polyunsaturated fatty acid

RCT. *See* Reverse cholesterol transport
 Remnant-like particles (RLP), 595–598
 Response-to-injury hypothesis, 3, 383, 538
 Restenosis. *See also* Post-PTCA restenosis
 as angioplasty limitation, 425–426
 mechanisms of, 421
 pathophysiology of, 419–420
 pharmacologic therapy for, 420–423
 prevention of, 424–425

Reverse cholesterol transport (RCT)
 apoA-I stimulation of, 251–253
 in atherosclerosis prevention, 599, 606
 CETP role in, 599–602, 606–608
 disorders of, 333–340
 HDL in, 240–241, 243, 245–251, 253–254,
 257–261
 impairment of, 599, 601–602
 LCAT in, 608
 in lipoprotein metabolism, 334
 lipoproteins/RBC roles in, 255–256
 organ perfusion study of, 240–261
 from spleen to blood serum, 245–246
 stages in, 240

SCP₂. *See* Sterol carrier protein 2
 SDGF. *See* SMC-derived growth factor
 Shear stress
 and glycosaminoglycan synthesis, 543–552
 measurements of
 at abdominal aorta stenosis, 111
 by AFM, 90–95
 at brachiocephalic bifurcation flow divider, 109

Shear-stress-response element (SSRE), 123,
 128, 155

SMC. *See* Smooth muscle cells
 SMC-derived growth factor (SDGF)
 and intimal SMC proliferation, 10
 SMC secretion of, 8

SMC-derived migration factor (SDMF),
 575–577

Smooth muscle cells (SMC)
 activation of, 526–528
 MHC isoforms in, 578–579
 migration of, 577
 and atherosclerosis, 2, 34
 PDGF and, 74, 78–79, 576
 and MMPs secretion, 501–506
 phenotypic change mechanism, 7–10
 phenotypic modulation of, 578
 in atherosclerotic coronary arteries,
 580–584
 MHC expression in, 579–580
 preatheromatous changes in, 580
 proliferation of
 cytokines moderation of, 160–161
 in developing atherosclerotic lesions, 74,
 313
 PKT inhibitors and, 171–174
 TF expression by, 187
 and TIMP secretion, 501, 504–506

SOD. *See* Superoxide dismutase
 Sodium salicylate (NaS), 559–560

Spleen, in RCT, 241, 245–251, 253–261

SSRE. *See* Shear-stress-response element

Sterol carrier protein 2 (SCP₂), 571–574

Stroke, 491
 cholesterol levels and, 496–488

Stromal potency precursor cells
 in human aortic intima, 25–30
 in hyperlipidemia patients, 30–32

Superoxide dismutase (SOD)
 and CS-LDL modification, 295, 299
 and lipoperoxides, 195

Suramin, 80–83

Syndrome X, 400

TGF β . *See* Transforming growth factor β
 α -Thrombin, 187

Thrombolysis
 NO and, 199–203
 PAI-1/tPA/uPA roles in, 367, 372–374

Thrombosis
 activated platelets and, 383
 antiplatelet drug prophylaxis for, 78
 atheromatous embolism and, 491–493
 and atherosclerosis, 462–463, 467–468
 as atherosclerotic sequelae, 185
 denuded endothelium and, 189
 PAI-1 and, 368, 394
 PAI-1 deficiency and, 374
 and restenosis, 420

Thromboxane A₂ (TXA₂)
 in angina pectoris, 195
 n-3 fatty acids and, 475

- Thromboxane A₂ (TXA₂) formation
 aspirin inhibition of, 195
 atherosclerosis and, 194, 383
Thromboxane B₂ (TXB₂), 388
Thrombus formation, 179
TIA. *See* Transient ischemic attack
Tight junctions
 and endothelial permeability, 106
 in high/low shear stress regions, 111–112
 shear stress influence on, 118
 Z/M ratio of
 in abdominal aorta, 113
 in aortic arch, 111
 in cultured endothelial cells, 113–114
TIMPs. *See* Tissue inhibitors of metalloproteinases
Tissue factor (TF)
 in atheroma, 186–187
 in coagulation pathway activation, 185
 immunohistochemical distribution of, 185–187
 LDL induction of, 187, 189
 macrophage production of, 186–188, 190
 SMC production of, 186–187
Tissue factor (TF) activity
 in atherosclerotic lesions, 187–189
 THF-induced, 189
Tissue factor (TF) expression
 in atheromatous plaque, 185, 190
 in atherosclerotic aorta, 186–187
 in fatty streaks, 187–188, 190
 in foam cells, 187–188
 by macrophages, 187
 in nonatherosclerotic aorta, 186, 188–189
 and plaque hypercoagulability, 187
 by SMC, 187
Tissue inhibitors of metalloproteinases (TIMPs), 164
 distribution of, 504–506
 SMC expression of, 501, 503–506
Tissue-type plasminogen activator (tPA), 127, 465
 biological roles of, 377–380
 in fibrinolytic system, 180, 367–368
 localization of, 178
 in thrombolysis, 367, 372–374
Tissue-type plasminogen activator (tPA) deficiency, 369–370
Tissue-type plasminogen activator (tPA) genes, 368–369
T lymphocytes
 in atherogenesis, 1, 41
 in atherosclerosis, 40–53
 CD4+/CD8+ cells, 45
 cytokine production by, 123
 hypercholesterolemia and, 41–42, 44
 in macrophage-SM fibrobliferative response, 2
TNF- α . *See* Tumor necrosis factor- α
tPA. *See* Tissue-type plasminogen activator
Transforming growth factor- β (TGF- β). *See also* Cytokines
 and SMC proliferation, 50
Transforming growth factor β (TGF β), 2, 8, 530
 in macrophage-SMC fibroproliferative response, 2
 and SMC proliferation, 161
Transient ischemic attack (TIA), 491
 NSAIDs and, 559
Triglyceride levels. *See also* Familial hypertriglyceridemia
 longitudinal changes in, 510–513
Tumor necrosis factor- α (TNF- α), 44, 46, 48, 50, 123, 187, 279. *See also* Cytokines
 and atherosclerotic lesion progression, 123
 and EC cAMP levels, 384
 HB-EGF induction by, 159
 intimal expression of, 44
 in macrophage-SM fibroproliferative response, 2
 and M-CSF production, 160
 and MMPs induction, 501, 503, 505–506
 NOS induction by, 586–587
 production of, 562, 564–569
 and SMC phenotype change, 8–9
 and vascular wall injury, 526, 528
TXA₂. *See* Thromboxane A₂
U PA. *See* Urinary-type plasminogen activator; Urokinase plasminogen activator
urinary-type plasminogen activator (uPA)
 in fibrinolytic process, 180
 localization of, 178
Urokinase-type plasminogen activator (uPA)
 biological roles of, 377–380
 in cell-mediated proteolysis, 368
 deficiency of, 369–370
 in fibrinolytic system, 367–268
V ascular cell adhesion molecule-1 (VCAM-1), 33
 clinical application of, 126
 cytokine induction of, 159, 526, 528
 in ECs, 498–499
 EPA effects on, 478–479
 expression of, 159
 identification of, 123–125
 IL-1 induction of, 475
 leukocyte selectivity of, 159
 lyso-PC up-regulation of, 541–542
 shear stress effect on, 148–155

- Vascular extracellular matrix, 162–164
- Vascular smooth muscle cells (VSMC)
 estrogen receptor in, 592–594
 G_i/S inhibition in, 590–591
 NOS induction in, 586–589
- VCAM-1. *See* Vascular cell adhesion molecule-1
- VCAM-1/VLA-4 adhesive interaction, 124–125
- Very high density lipoprotein (VHDL), 606–608
- Very low density lipoprotein (VLDL)
 alcohol intake and, 628
 and atherosclerosis, 313
 metabolism of, 333
 in RLP, 595, 598
 in serum lipoprotein metabolic pathway, 334
- Very low density lipoprotein (VLDL) receptor
 lipoprotein specificity of, 218–219
 in plasma lipoprotein metabolism, 222–223
 sequence conservation, 219–222
- VHDL. *See* Very high density lipoprotein
- Visceral fat accumulation
 and atherosclerosis, 400
 factors inducing, 400–403
 and metabolic and circulatory disorders, 403
 in normal body weight subjects, 399–400
- Visceral fat obesity, 399–405
- Visceral fat syndrome, 400, 404–405
- Vitronectins (Vn)
 in atherosclerotic lesions, 524–525
 as PAI-1 carrier protein, 177–178
 and PAI-1 localization, 180
- VLA-4. *See* Integrin receptor
- VLDL. *See* Very low density lipoprotein
- Vn. *See* Vitronectin
- von Willebrand factor (vWF), 18, 179
- VSCM. *See* Vascular smooth muscle cells
- W**eibel-Palade bodies, 18–19, 33
- X**anthine–xanthine oxidase system
 adhesion molecule activation of, 141, 143–146
 in EC hydroxyl production, 134
- Z**/M. *See* Zonular type/macular type ratio
- Zonular type/macular type ratio (Z/M), 109, 111, 113, 119

